SiNOPSEE Therapeutics Pvt Ltd is a bio-pharmaceutical company founded in 2017 with its headquarters in Singapore. The company focuses on the discovery, design, and development of small molecular weight compounds for the treatment of chronic diseases. Originating from the scientifically accredited Agency for Science, Technology & Research (A*STAR), SiNOPSEE’s R&D HQ and main holding is also based out of Singapore. The company's small molecule inhibitors were identified using a versatile high-throughput screening technology and were optimized for potency and selectivity, employing in-silico molecular modeling techniques. Their lead molecules exhibit significant potency, selectivity, and show promise in in-vitro (cell lines), ex-vivo (organoid), and in-vivo (rodent) models. SiNOPSEE plans to develop its lead molecule to early stage clinical trials and subsequently out-license or co-develop the compound(s) with major pharmaceutical players for advanced clinical trials and commercialization. With a focus on biotechnology, SiNOPSEE Therapeutics Pvt Ltd presents a compelling investment opportunity in the development of innovative treatments for chronic diseases.
There is no investment information
No recent news or press coverage available for SiNOPSEE Therapeutics Pte Ltd.
We care about your data, and we'd love to use cookies make your experience better.
